Back to Search
PABLO ELIZALDE, M.D.
M.D.
Cardiovascular Disease Physician
NPI: 1831290055IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
045206(GA)
CMS Specialties
PrimaryCARDIOVASCULAR DISEASE (CARDIOLOGY)
Education
UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
Class of 1991
Research & Publications (13)
Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth.
PMID 19103753·Mol Cell Biol·2009
7-preclinical
TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.
PMID 18061162·Exp Cell Res·2008
7-preclinical
Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
PMID 17440047·Mol Endocrinol·2007
7-preclinical
Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.
PMID 16799639·Oncogene·2006
7-preclinical
Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway.
PMID 16517711·J Immunol·2006
7-preclinical
Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.
PMID 15923602·Mol Cell Biol·2005
7-preclinical
[Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer].
PMID 15628299·Medicina (B Aires)·2004
7-preclinical
Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
PMID 15122317·Oncogene·2004
7-preclinical
Involvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomas.
PMID 14503801·Breast Cancer Res Treat·2003
7-preclinical
Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
PMID 12529413·Mol Cell Biol·2003
7-preclinical
Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
PMID 12209601·Int J Cancer·2002
7-preclinical
Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors.
PMID 11281653·Exp Cell Res·2001
7-preclinical
Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells.
PMID 11244498·Oncogene·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4700 WATERS AVE STE 400
SAVANNAH, GA 31404 - Phone
- (912) 273-1100
Quick Facts
- NPI
- 1831290055
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 35
- Publications
- 13
Are you this provider?
Claim Your Profile